IQVIA Holdings, Inc. · NYSE:IQV
IQVIA — Quintiles — William Blair 35th Annual Growth Stock Conference (June 2015)
18 slides from IQVIA's conference presentation, Jun 9, 2015
Slide 1: William Blair 35th Annual Growth Stock Conference
William Blair 35th Annual Growth Stock Conference June 9, 2015 © Copyright 2014 Quintiles NYSE: Q
Slide 2: Forward Looking Statements and Use of Non-GAAP Financial Measures
Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements refl
Slide 3: Quintiles: Leader in BioPharma Services
Quintiles Leader in BioPharma Services Growing Markets Differentiated Deep & Diverse Service Offerings Customer & Relationships Relationships Clear Industry Leader Financial Strength and Execution Momentum 3
Slide 4: Strategic Agenda
Strategic Agenda • Profitable growth at above market rates • Investments leveraging our scale • World class customer relationship management • Productivity, delivery & quality • Top leadership and people development Connecting insights with superior delivery for better outcomes 4
Slide 5: Track Record of Profitable Growth and Consistency
Track Record of Profitable Growth and Consistency Long-term performance underpinned with a diversified customer portfolio Service Revenues Adjusted EBITDA(1) ’11 – ’14 CAGR = 8.1% ’11 – ’14 CAGR = 13.7% 4,400 $4,166 $4,191 800 $720 $728 $3,808 $3,692 $3,295 $612 3,300 600 $544 $490 $ Millions $ Mill
Slide 6: Financial Highlights
Financial Highlights Q1 Financial Highlights Other Highlights Constant Currency Announcement of Clinical Laboratory 10.5% Net New Business Growth Services Joint Venture with Quest Diagnostics Constant Currency Revenue 8.4% Growth(1) Completion of $2.75bn debt refinancing • Extends maturities and
Slide 7: The Current Biopharma Market
The Current Biopharma Market Increasing approvals indicate biopharma industry health • 41 novel drugs approved by FDA CDER in 2014 • 10 approved in Q1 2015 vs. 8 in Q1 2014 • EMA provided 82 positive opinions in 2014 • Significant growth in biotech funding Robust development pipeline offers future p
Slide 8: Attractive and Growing Market
Attractive and Growing Market ~$200bn total market across both segments with increasing outsourcing penetration which drives estimated growth of 6% – 8% per year from 2014 – 2017 Approval Phase Commercial Phase I Phase II Phase III Healthcare Delivery IV Product Development Services Integrated Healt
Slide 9: Market drivers
Market drivers We understand the needs of biopharma and how the industry is evolving Simplify the complex – Improve Increase R&D Provide global investigator & productivity scientific patient access expertise Using real- Increasing Increasing world data & demand for importance of analytics to evidenc
Slide 10: Product Development
Product Development Improving the probability of success using science, technology and global delivery Ph - I Ph - II Ph - III Ph-IIIB & IV Product Development Services • Core segment representing 73% of Consolidated Deep science, therapeutic, & Service Revenues and 90% of Segment Income from regula
Slide 11: Integrated Healthcare Services
Integrated Healthcare Services Improving the probability of commercial success Phase II & III Commercial Healthcare Delivery Integrated Healthcare Integrated Healthcare Services Services Offerings • IHS segment represents 27% of Consolidated Service Commercial Services: • Contract Sales Revenues and
Slide 12: Deep Customer Relationships
Deep Customer Relationships Largest backlog in industry with diversification and sustainability • Helped develop or commercialize 2014’s top-75 best-selling drugs on the market • Worked with the top-20 biopharma companies ranked by 2013 revenues in each of last 12 years • 11 customer accounts genera
Slide 13: The Quintiles Difference
The Quintiles Difference The integration of our assets creates differentiated value Global harmonized Deep scientific, therapeutic, best in class Technology & informatics & regulatory expertise processes & workforce 950 >23 Quintiles Infosario™ Platform Medical doctors Prime sites Planning & Design
Slide 14: Quintiles: Differentiated market leader
Quintiles Differentiated market leader Strong free cash flow Best in industry operating margins Deep and diverse customer relationships Consistent long term financial performance First mover advantage with Clinical Development Informatics technology Largest backlog in Market leader in industry Produ
Slide 15: Appendix
Appendix QUINTILES’ 15
Slide 16: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation Adjusted EBITDA Reconciliation LTM period ended (In Thousands) 3/31/2015 2014 2013 2012 2011 Non-GAAP Adjusted EBITDA: Net Income Attributable to Quintiles Transnational Holdings Inc. $352,598 $356,383 $226,591 $177,546 $241,772 Net income (loss) attributable to noncon
Slide 17: Constant Currency Reconciliation Service Revenues and Income from Operations
Constant Currency Reconciliation Service Revenues and Income from Operations (millions of dollars) Three Months Ended March 31 Year on Year Growth Exchange Exchange Consolidated Actual Impact Constant Actual Impact Constant Service Revenues $ 1,030.0 $ (59.0) $ 1,089.0 2.5% (5.9%) 8.4% Income from O
Slide 18: Reconciliation of Net Income to Non-GAAP Adjusted Net Income and Diluted Adjusted EPS
Reconciliation of Net Income Attributable to Quintiles to Non-GAAP Adjusted Net Income and Diluted Adjusted EPS Three Months Ended March 31 (millions of dollars) 2015 1 2014 1 EPS EPS Net Income Attributable to Quintiles $ 86.4 $ 0.68 $ 90.2 $ 0.68 Restructuring Costs 5.3 0.04 1.0 0.01 Adjustment to
Quintiles — William Blair 35th Annual Growth Stock Conference (June 2015) on 6ix